Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Lidocaine in Cervical Cancer Surgery
NCT05560035Unknown
- Sponsor
- General Hospital of Ningxia Medical University
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of Lidocaine Hydrochloride Injection, without epinephrine in Cervical Cancer (CC) (2 arms), sponsored by General Hospital of Ningxia Medical University. Primary endpoints: Changes from Baseline THBS2, Changes from Baseline MMP-2 and 2 more. Status: unknown.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05560035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560035.